NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update Oncology

Drug Safety Updates: crizotinib and vemurafenib

The Medicines Healthcare and Regulatory Agency (MHRA) have published new safety information relating to the following:

Crizotinib: Risk of cardiac failure.  There have been reports of severe, sometimes fatal, cases of cardiac failure in patients treated with crizotinib.  To see MHRA advice for healthcare professionals including recommended monitoring click here.  The West of Scotland Cancer Network protocol for crizotinib will be updated to reflect this advice.

Vemurafenib: Risk of potentiation of radiation toxicity.  Prescribers should be aware of the risk of potentiation of radiation toxicity with vemurafenib when given before, during or after radiotherapy.  To see MHRA advice for healthcare professionals click here.  The West of Scotland Cancer Network protocol for vemurafenib will be updated to reflect this advice.